Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Context Therapeutics Inc.CNTX · Entity 7406 | Director | June 24, 2026 | June 26, 2026 |
| ESSA Pharma Inc.EPIX · Entity 15763 | Director | March 25, 2024 | March 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Context Therapeutics Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-06-23 | Direct | 45,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.
ESSA Pharma Inc.
Report date March 25, 2024 · Filed March 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.04 · Expires 2034-03-25 | Direct | 50,000 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 50,000 · Balance 50,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:13 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001628280-26-045762 · wk-form4_1782504828.xml · derivative · entry 1 Kantoff Philip W. · CIK 0001866025 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 21:28 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 123,500 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001842952-25-000077 · wk-form4_1749763711.xml · derivative · entry 1 Kantoff Philip W. · CIK 0001866025 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,500 Underlying: Common Stock · 123,500 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 12, 2026 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2026 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 11:50 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001842952-24-000046 · wk-form4_1718365807.xml · derivative · entry 1 Kantoff Philip W. · CIK 0001866025 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| March 25, 2024 Filed Mar 28, 2024 16:34 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | GrantOptions · Derivative | 50,000 | $0.00 Strike: $9.04 | $0.00 |
DisclosureSEC source: 0000950172-24-000135 · form4.xml · derivative · entry 1 Kantoff Philip W. · CIK 0001866025 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2034-03-25 Read SEC document |
| May 31, 2023 Filed May 31, 2023 20:53 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001842952-23-000062 · wf-form4_168556641370866.xml · derivative · entry 1 Kantoff Philip W. · CIK 0001866025 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) May 31, 2024 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2024 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:10 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001842952-22-000059 · wf-form4_165428700930146.xml · derivative · entry 1 Kantoff Philip W. · CIK 0001866025 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: 1.The option vests and becomes exercisable on the earlier of (i) June 2, 2023 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2023 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.